A letter posted to the site of the FDA indicates that the agency approved the new drug application, or NDA, submitted by Apellis Pharmaceuticals for the use of Syfovre for intravitreal use for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis Pharmaceuticals shares had been halted for trading this afternoon, pending news. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals put volume heavy and directionally bearish
- Citi opens ‘positive 30-day Catalyst Watch’ on Apellis into FDA decision
- JPMorgan sees Apellis rally with FDA action date fast approaching
